A NEW TOOL TO DEBRIDE INFECTED IMPLANTS

In the realm of dental health, oral biofilms—commonly known as dental plaque—are often the culprits behind severe dental issues, including bone degradation, tooth loss, and dental implant failure. Despite advancements in oral care, we still rely heavily on antibiotic treatments to manage biofilm-related problems. However, the Norwegian-based company Corticalis AS is set to revolutionize this space with its patented NuBone Gel and NuBone® Debrilator, a titanium-made brush.NuBone Gel showcases a groundbreaking "biomimetic" approach, mimicking biological processes to tackle the problem effectively. Unlike conventional treatments, this gel operates on two fronts. Firstly, it possesses antibacterial properties to halt the growth and spread of harmful microbes. Secondly, its abrasive features enable successful debridement, essentially scrubbing away established biofilms. In other words, the gel prevents and removes existing biofilm formations, offering a comprehensive solution for maintaining oral health. Corticalis has a unique platform to demonstrate the efficacy and market viability of NuBone Gel. As we strive to improve dental care without resorting to antibiotics, innovations like NuBone Gel come as a breath of fresh air, or should we say, a "breath of healthy gums and teeth." Through its biomimetic capabilities, NuBone Gel promises to be another product on the dental aisle and a game changer in how we approach oral health. This initiative places Corticalis AS on the frontline of dental debridement technology, opening a new chapter in non-antibiotic dental care solutions. This innovation is a testament to how scientific research can overcome prevailing challenges, providing more effective and sustainable options for dental health. It exemplifies the transformative power of research and innovation in healthcare, promising a brighter future for dental care worldwide.

Corticalis AS has developed NuBone Gel - a novel and patented gel for the abolishment of oral biofilms that, in severe cases, induce bone degradation, tooth loss and dental implant failure and a brush, NuBone®Debrilator made out of titanium. Our product’s biomimetic mode of action and its multiple effects, both antibacterial and abrasive to enable debridement, allows for an ultra-effective, safe and predictable biofilm removal. Corticalis will lead the project, which will focus on product maturation, preparation of the market launch and commercialisation of our non-antibiotic-based product. The main barriers for Corticalis going forward are prevailing technical and market-related challenges. This project will enable performing the final optimisation on the packaging, preparing a pilot production to supply testing activities and clinical studies to reach the CE certification, demonstrating the product to end-users (dentists, hygienists, dental surgeons and patients), and preparing the market launch in Europe and US. This RCN program provides a unique opportunity for Corticalis to showcase the potential of our innovation and gain market intelligence. Completing the project objectives is important for ensuring a successful entrance to the market and commercialization of our innovative gel product. Our products will be a game changer in improving dental care, entering the peri-implant and periodontal disease treatment market, which has a business potential over 470M€/year in Europe. This project will put Corticalis in the frontline of dental care debridement, with the opportunity to generate accumulated revenues of 138M€ until 2030.